Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B GOTTLIEB

Showing results (371-380 of 523) with videos related to

Pageof 53
Sort By:
Journal of the American Academy of Dermatology|March 12, 2005
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trialCraig L Leonardi, Kim A Papp, Kenneth B Gordon, et al.
Rheumatology (Oxford, England)|June 27, 2018
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)Alice B Gottlieb, Vibeke Strand, Mitsumasa Kishimoto, et al.
Arthritis Care & Research|June 23, 2015
Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III TrialArthur Kavanaugh, Lluís Puig, Alice B Gottlieb, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 1989
Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytesR M Grossman, J Krueger, D Yourish, et al.
The British Journal of Dermatology|July 12, 2020
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)K B Gordon, R B Warren, A B Gottlieb, et al.
American Journal of Pharmaceutical Education|March 5, 2016
The Validation of a Case-Based, Cumulative Assessment and Progressions ExaminationRebecca L Brady, Adeola O Coker, Jeffrey T Copeland, et al.
American Journal of Clinical Dermatology|January 18, 2020
Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) InitiativeLourdes M Perez-Chada, Nicole F Salame, Adam R Ford, et al.
Journal of the American Academy of Dermatology|October 25, 2003
CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized studyAlice B Gottlieb, Thomas B Casale, Ellen Frankel, et al.
The Journal of Investigative Dermatology|October 21, 2011
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasisKenneth B Gordon, Richard G Langley, Alice B Gottlieb, et al.
Journal of Drugs in Dermatology : JDD|October 17, 2017
Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With PsoriasisRobert Bissonnette, Francisco Kerdel, Luigi Naldi, et al.
Pageof 53

Showing results (371-380 of 523) with videos related to

Sort By:
Pageof 53
Journal of the American Academy of Dermatology|March 12, 2005
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trialCraig L Leonardi, Kim A Papp, Kenneth B Gordon, et al.
Rheumatology (Oxford, England)|June 27, 2018
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)Alice B Gottlieb, Vibeke Strand, Mitsumasa Kishimoto, et al.
Arthritis Care & Research|June 23, 2015
Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III TrialArthur Kavanaugh, Lluís Puig, Alice B Gottlieb, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 1989
Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytesR M Grossman, J Krueger, D Yourish, et al.
The British Journal of Dermatology|July 12, 2020
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)K B Gordon, R B Warren, A B Gottlieb, et al.
American Journal of Pharmaceutical Education|March 5, 2016
The Validation of a Case-Based, Cumulative Assessment and Progressions ExaminationRebecca L Brady, Adeola O Coker, Jeffrey T Copeland, et al.
American Journal of Clinical Dermatology|January 18, 2020
Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) InitiativeLourdes M Perez-Chada, Nicole F Salame, Adam R Ford, et al.
Journal of the American Academy of Dermatology|October 25, 2003
CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized studyAlice B Gottlieb, Thomas B Casale, Ellen Frankel, et al.
The Journal of Investigative Dermatology|October 21, 2011
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasisKenneth B Gordon, Richard G Langley, Alice B Gottlieb, et al.
Journal of Drugs in Dermatology : JDD|October 17, 2017
Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With PsoriasisRobert Bissonnette, Francisco Kerdel, Luigi Naldi, et al.
Pageof 53